Based on the Thelansis market insight report on Acute Respiratory Distress Syndrome (ARDS) which provides a clear understanding on disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2020 to 2030.
The total incidence cases of ARDS varies between 158 to 190 cases per 100,000 population in the USA.
Comprehensive insight on patient segmentation based on severity (mild, moderate and severe), by risk factors (Pneumonia, Sepsis, Trauma, Aspiration, Pancreatitis, Others) and Non-risk factor associated, Patients eligible for mechanical ventilation (Noninvasive ventilation, and Invasive ventilation) has been provided into the epidemiology (Incidence and Prevalence) section of the Acute Respiratory Distress Syndrome (ARDS) and its treatment in the 8 MM coun-tries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.
In terms of pharmacologic therapies, Several drug candidates are in Phase III, II and I stages of development by various companies. Key assets among these are, Traumakine from Faron Pharmaceuticals, Bio-11006 from BioMarck Pharmaceuticals, IC14 from Implicit Bioscience, Ulinastatin from Techpool Bio-Pharma, MultiStem from Athersys, AP301 from Apeptico Forschung und Entwicklung GmbH. Among these key assets, some of the assets are being designated as orphan drugs and fast track. The launch of key assets will positively impact the overall market from 2020 to 2030 in 8 MM countries. While there is a lot of competitive activity going on in the pipeline for ARDS, companies like United Therapeutics, Chiesi Farmacetuci, Savara Pharmaceuticals, Celerion, Mallinckrodt Pharmaceuticals and Roche have their product in the early stages of development.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,